What Is the Treatment of Warm Autoimmune Hemolytic Anemia?
Warm autoimmune hemolytic anemia (wAIHA) is a haemolytic disorder in which IgG autoantibodies target red blood cells, driving their destruction and causing falling haemoglobin levels. Prompt, structured treatment is needed to interrupt haemolysis and restore red cell mass, while managing the associated risk of thrombosis.
Treatment Approach
First-line management centres on corticosteroid therapy; in severe presentations or when the initial response is inadequate, an additional immunomodulatory agent is considered early. Supportive measures addressing haemoglobin recovery and thrombosis risk form part of the overall strategy.
The complete treatment sequence, decision thresholds, and full supportive regimen are in the structured protocol below.
Clinical Goal
Improvement in haemoglobin levels with achievement of a complete response
References
DOI: 10.33590/emjhematol/GBUF7192
- Corticosteroids remain first-line therapy for wAIHA, although the addition of rituximab should be considered early in severe cases, and if there is no prompt response to steroids.
- Anticoagulant prophylaxis is recommended for patients with wAIHA to reduce the risk of thrombosis.
- Recombinant erythropoietin is recommended in patients with AIHA, including wAIHA, to stimulate the bone marrow, thereby boosting bone marrow compensation, improving haemoglobin levels, and reducing the need for transfusion, particularly in the first 15 days of haemolytic crisis.
View source ↗